Corrigendum to “Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial”

Corrigendum to “Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in... CORRIGENDUM JNCI J Natl Cancer Inst (2018) 110(7): djy096 doi: 10.1093/jnci/djy096 First published online May 24, 2018 Corrigendum CORRIGENDUM Corrigendum to “Neoadjuvant 5-FU or Capecitabine Plus Radiation On page 6, the sentence “Although we did observe a numeri- With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III cally greater number of deaths while on or within 45 days of ac- Randomized Clinical Trial” by Carmen J. Allegra et al. JNCI: J Natl tive treatment .. . this increase did not reach statistical Cancer Inst. 2015; 107(11): doi: 10.1093/jnci/djv248. significance and the overall survival among the arms was iden- tical HR ¼ 1.0)” should instead read as the following: “We ob- On page 4, the sentence “Further unplanned analysis that served a numerically greater number of deaths while on or within 45 days of active treatment ... and this increase did included only patients at high risk for recurrence (lymph node-positive and clinical stage TIII/IV disease) also demon- reach statistical significance but the overall survival among the arms was identical (HR ¼ 0.94).” strated ...” should instead read as the following: “Further unplanned analysis that included only patients at high risk for recurrence (pathologic lymph node-positive and pathologic On page 7 in the discussion, the sentence “An unplanned retro- stage TIII/IV disease) also demonstrated ...” spective exploratory analysis of only those patients with either clinical stage TIII with node positivity or those with T4 lesions showed ...” should instead read as the following: “An On page 5, the sentence “Although there were numerically more deaths (on treatment and within 45 days of completing unplanned retrospective exploratory analysis of only those patients with either pathologic stage TIII/IV with node positivity neoadjuvant treatment) in the capecitabine arms (4 and 5 vs 1 each for the capecitabine vs 5-FU arms, respectively), these dif- showed ...” ferences did not reach statistical significance (p¼0.64 Fisher’s exact test, post-amendment, 2 vs 9 deaths (0.091, pre and post- In addition, we have published a new Figure 5, which contains amendment, 3 vs 10 deaths)” should instead read as the follow- the corrected hazard ratios in both panel A and B that match ing: “There were numerically more deaths (on treatment and the original text. The hazard ratios were reversed in the original within 45 days of completing neoadjuvant treatment) in the figure, but the text in the results was correct. capecitabine arms (4 and 5 vs 1 each for the capecitabine vs 5- FU arms, respectively), and these differences did reach statisti- The authors regret the errors. cal significance (p¼0.037 Fisher’s exact test, post-amendment, 2 vs 9 deaths (0.056, pre and post-amendment, 3 vs 10 deaths).” © The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com Downloaded from https://academic.oup.com/jnci/article-abstract/110/7/794/5003343 by Ed 'DeepDyve' Gillespie user on 11 July 2018 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JNCI: Journal of the National Cancer Institute Oxford University Press

Corrigendum to “Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial”

Free
1 page

Loading next page...
1 Page
 
/lp/ou_press/corrigendum-to-neoadjuvant-5-fu-or-capecitabine-plus-radiation-with-or-hEL4umIJ9U
Publisher
Oxford University Press
Copyright
© The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com
ISSN
0027-8874
eISSN
1460-2105
D.O.I.
10.1093/jnci/djy096
Publisher site
See Article on Publisher Site

Abstract

CORRIGENDUM JNCI J Natl Cancer Inst (2018) 110(7): djy096 doi: 10.1093/jnci/djy096 First published online May 24, 2018 Corrigendum CORRIGENDUM Corrigendum to “Neoadjuvant 5-FU or Capecitabine Plus Radiation On page 6, the sentence “Although we did observe a numeri- With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III cally greater number of deaths while on or within 45 days of ac- Randomized Clinical Trial” by Carmen J. Allegra et al. JNCI: J Natl tive treatment .. . this increase did not reach statistical Cancer Inst. 2015; 107(11): doi: 10.1093/jnci/djv248. significance and the overall survival among the arms was iden- tical HR ¼ 1.0)” should instead read as the following: “We ob- On page 4, the sentence “Further unplanned analysis that served a numerically greater number of deaths while on or within 45 days of active treatment ... and this increase did included only patients at high risk for recurrence (lymph node-positive and clinical stage TIII/IV disease) also demon- reach statistical significance but the overall survival among the arms was identical (HR ¼ 0.94).” strated ...” should instead read as the following: “Further unplanned analysis that included only patients at high risk for recurrence (pathologic lymph node-positive and pathologic On page 7 in the discussion, the sentence “An unplanned retro- stage TIII/IV disease) also demonstrated ...” spective exploratory analysis of only those patients with either clinical stage TIII with node positivity or those with T4 lesions showed ...” should instead read as the following: “An On page 5, the sentence “Although there were numerically more deaths (on treatment and within 45 days of completing unplanned retrospective exploratory analysis of only those patients with either pathologic stage TIII/IV with node positivity neoadjuvant treatment) in the capecitabine arms (4 and 5 vs 1 each for the capecitabine vs 5-FU arms, respectively), these dif- showed ...” ferences did not reach statistical significance (p¼0.64 Fisher’s exact test, post-amendment, 2 vs 9 deaths (0.091, pre and post- In addition, we have published a new Figure 5, which contains amendment, 3 vs 10 deaths)” should instead read as the follow- the corrected hazard ratios in both panel A and B that match ing: “There were numerically more deaths (on treatment and the original text. The hazard ratios were reversed in the original within 45 days of completing neoadjuvant treatment) in the figure, but the text in the results was correct. capecitabine arms (4 and 5 vs 1 each for the capecitabine vs 5- FU arms, respectively), and these differences did reach statisti- The authors regret the errors. cal significance (p¼0.037 Fisher’s exact test, post-amendment, 2 vs 9 deaths (0.056, pre and post-amendment, 3 vs 10 deaths).” © The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com Downloaded from https://academic.oup.com/jnci/article-abstract/110/7/794/5003343 by Ed 'DeepDyve' Gillespie user on 11 July 2018

Journal

JNCI: Journal of the National Cancer InstituteOxford University Press

Published: May 24, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off